Sales of a new hepatitis-C drug helped boost Johnson & Johnson's second-quarter revenue by 9.1%, but executives said they don't expect the pill's sales to keep pace, and outlined several challenges facing the overall health-care market.. Sales of the hepatitis-C pill, called Olysio, reached $831 million world-wide in the second quarter, compared with $354 million in the first quarter.. Olysio...
  